Indivior Underscores Commitment to Putting Patients First during this Recovery Month

Rethinkopioidaddiction.com encourages people to rethink their perceptions of addiction,
recovery, and treatment

Slough, UK and Richmond, VA, September 22, 2020 – September is Recovery Month, a time to
celebrate people in recovery and advocate for those who remain under-diagnosed, under-treated and
under-supported as they struggle with opioid use disorder (OUD). In our continued efforts to deepen
our commitment to patients with OUD, Indivior has launched a new informational website,
RethinkOpioidAddiction.com. Presenting scientific evidence, easy-to-understand explanations and links
to public health resources, the website encourages people to “rethink” their perceptions of addiction,
recovery and treatment.

“Consistent with our commitment to advancing the public’s understanding of opioid use disorder,
RethinkOpioidAddiction.com was developed to focus on the science to help inform and raise awareness
of the patient journey,” said Mark Crossley, Chief Executive Officer of Indivior. “By helping to educate on
how opioid addiction rewires the brain, Indivior aims to tackle the stigma and raise awareness of opioid
use disorder as a treatable disease and not a moral failing. We know too much about this chronic
disease for so many people to continue to struggle.”

Now more than ever, people need accurate, scientific information and access to evidence-based
treatment and counseling. The social isolation and economic dislocation brought on by the COVID-19
pandemic is preventing people from accessing mental and emotional support groups, which are critical
for those managing their recovery.1

While a recent survey from the Substance Abuse and Mental Health Services Administration (SAMHSA)
shows promising trends in the state of the opioid epidemic in the U.S., it also notes that substance
misuse and mental illness continue to be major problems for Americans.2 According to new data from
the National Survey on Drug Use and Health (NDUH), OUD has decreased from 2.1 million in 2018 to 1.6
million in 2019.2 The report also states that “efforts to increase access to Medication-Assisted
Treatment and psychosocial/community recovery supports have had a positive effect.”3 However,
among those people who do receive treatment for OUD, the most common treatment is still outpatient
counseling (approximately 60% of patients), with only 12.5% of patients receiving medications for OUD.
4 Furthermore, although the number of people with OUD has decreased2, data released by the Centers for
Disease Prevention and Control (CDC) show that drug overdose deaths reached a record high in 2019,
reversing the 2018 decline.5 According to the CDC, the reported 12-month-ending provisional counts of
drug overdose deaths in February 2020 was 72,780, a 7.6 percent increase over the 67,632 counts taken
in February 2019.5

The impact of the intersection of the COVID-19 pandemic and the OUD epidemic in 2020 has yet to be
fully understood. 6A September 2020 brief issued by the American Medical Association showed that
more than 40 states have reported increases in opioid-related mortality.7

“Stakeholder collaboration, comprehensive planning and funding will be critical in the long-term to
prevent this epidemic from taking more lives,” said Christian Heidbreder, Chief Scientific Officer of
Indivior. “By coming together to remove barriers to treatment, fight against addiction stigma, and
educate the public on the science of addiction, we can address this overdose crisis and help move those
struggling with opioid use disorder toward a path to recovery.”
 

Forward-Looking Statements
This press release contains certain statements that are forward-looking, and which should be
considered, amongst other statutory provisions, in light of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements
involve risk and uncertainty as they relate to events or circumstances that may or may not occur in the
future. Actual results may differ materially from those expressed or implied in such statements because
they relate to future events. Forward-looking statements include, among other things, statements
regarding the Indivior Group’s financial guidance for 2020 and its medium- and long-term growth
outlook, its operational goals, its product development pipeline and statements regarding ongoing
litigation. Various factors may cause differences between Indivior's expectations and actual results,
including: factors affecting sales of Indivior Group’s products; the outcome of research and development
activities; decisions by regulatory authorities regarding the Indivior Group’s drug applications; the speed
with which regulatory authorizations, pricing approvals and product launches may be achieved; the
outcome of post-approval clinical trials; competitive developments; difficulties or delays in
manufacturing; the impact of existing and future legislation and regulatory provisions on product
exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory
action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may
arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks
related to legal proceedings, including the ongoing investigative and antitrust litigation matters; the
Indivior Group’s ability to protect its patents and other intellectual property; the outcome of patent 
infringement litigation relating to Indivior Group’s products, including the ongoing ANDA lawsuits;
changes in governmental laws and regulations; issues related to the outsourcing of certain operational
and staff functions to third parties; uncertainties related to general economic, political, business,
industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings,
internal reorganizations, product recalls and withdrawals and other unusual items. This press release
does not constitute an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire or
dispose of shares in the Company to any person in any jurisdiction to whom it is unlawful to make such
offer or solicitation.

About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing
medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and cooccurring disorders of
addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a
pipeline of product candidates designed to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder.
Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals
globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com
to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Media Contacts
US
IndiviorMediaContacts@indivior.com
+1 804-594-0836

UK
Tulchan Communications
+44 207-353-4200

Investor Contact
Jason Thompson
Indivior Vice President, Investor Relations
+1 804-402-7123
Jason.Thompson@indivior.com